Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–86 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: LEO Pharma Clear all
Active, not recruiting Phase 2 Interventional

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

NCT03886246
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Auburn Hills, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 10, 2026, 6:53 AM EDT
Recruiting No phase listed Observational

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

NCT05938478
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Tralokinumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

NCT01555463
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

NCT03683719
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Tucson, Arizona • Hialeah, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed No phase listed Observational

A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea

NCT03193372
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid (Finacea Foam, BAY39-6251)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Palm Harbor, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

NCT02361216
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

NCT02251652
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Ingenol Mebutate, Cryotherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

NCT02305888
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

NCT00704262
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus hydrocortisone (LEO 80190)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

NCT02446223
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Inggenol Mebutate 0.015%
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 10, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebos
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 10, 2026, 6:53 AM EDT